A Study of GZR18 Injection in Obese/Overweight Patients

Phase 2 Completed 340 enrolled Gan and Lee Pharmaceuticals, USA

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a multicenter, randomized, placebo-controlled phase II clinical study to evaluate the efficacy, safety, tolerability, and pharmacokinetics of GZR18 injection in Chinese adult obese/overweight subjects.

Timeline

Start: 2023-06-08
Primary completion: 2024-06-05
Completion: 2024-06-05

Outcome

Met primary endpoint

paper ranged from -9.75% to -16.69% with bofanglutide, compared with -1.15% with placebo (all p < 0.001 versus placebo). PMID 41760612 ↗

Publications

Ji L, Gao L, Tian J, Dong R, Zhang Z, Shu H, Zhao J, Zhao L, He A, Xie T, Li Y, Chen W. Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. Signal Transduct Target Ther. 2026 Feb 27;11(1):73. doi: 10.1038/s41392-026-02586-8.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bofanglutide	Protein / enzyme biologic	12 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	18 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	24 mg	Subcutaneous
Subject	Bofanglutide	Protein / enzyme biologic	48 mg	Subcutaneous